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Background: The perioperative risk of non-cardiac surgery (NCS) in the patients on antiplatelet therapy
after percutaneous coronary intervention (PCI) remains unclear.
Methods: This study was a retrospective and single center study. Between January 2008 and December
2011, 198patientswhohad already received PCI underwentNCS in our hospital. Among them, 63patients
underwent surgery on dual antiplatelet therapy (DAPT group) and 88 patients on single antiplatelet
therapy (SAPT group). We compared bleeding events and cardiovascular events during perioperative
period between the two groups.
Results: There was no stent thrombosis in either group. The bleeding events in the DAPT group weretent thrombosis
ntiplatelet therapy
eparin-bridge
signiﬁcantly higher than that in the SAPT group (9.5% vs 2.3%, p=0.049). There was no difference in
events between with or without heparin-bridge in the SAPT group.
Conclusions: The frequency of bleeding events was higher in the DAPT group. Both bleeding and cardio-
vascular events with aspirin alone were low in our study. It may be safe to undergo NCS with SAPT after
PCI.
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Antiplatelet therapy (APT) plays a central role in the treatment
f patients receiving stent deployment [1]. The most important
tent thrombosis (ST) predictor is premature discontinuation of
ual antiplatelet therapy (DAPT) [2,3]. Apart from non-compliance,
he most common reason for early discontinuation of either DAPT
r single antiplatelet therapy (SAPT) is the need for non-cardiac
urgery (NCS), accounting for one-third of cases [3].
According to current American College of Cardiology/American
eart Association (ACC/AHA) guidelines, approximately two-thirds
f allNCSprocedures in theﬁrst year after indexpercutaneouscoro-
ary intervention (PCI) are classiﬁed as moderate to high risk for
ajor adverse cardiac events (MACE) [4–6]. MACE, particularly ST,
s a concern after discontinuation of APT; however, its continuation
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is associated with bleeding risk. The perioperative management
of APT remains controversial because there is limited amount of
evidence to suggest what strategies are effective in preventing
bleeding or cardiovascular events.
In this study, we investigated NCS outcomes in patients who
had received either bare-metal stents (BMS) or drug-eluting stents
(DES), comparing between DAPT and SAPT.
Methods
Study patients
The present study included 198 patients who had undergone
NCSafter successful PCI between January2008andDecember2011,
and the data were retrospectively analyzed. The local ethics com-
mittee approved this study. All patients had already undergone
PCI with either BMS or DES. The treating physician determined
the type of stent used at the PCI procedure. Patients with a BMS
were prescribed aspirin (100mg/day) and thyenopyridine (ticro-
pidin 200mg/day or clopidogrel 75mg/day) for 30 days. Patients
with a DES usually were prescribed aspirin and thienopyridine
clopidogrel for 6 months or longer, at the discretion of the treat-
ing physician. NCS were performed after stent deployment during
served.
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28±290 days. If the patients took DAPT before surgery in SAPT
roup, only thyenopyridine was discontinued 5–14 days before
urgery.
nclusion criteria
The inclusion criteria were (1) patients who underwent NCS
fter stent deployment and (2) patients who received DES or BMS.
CS was deﬁned as surgical procedure in the operation room and
equired local or general anesthesia (abdominal, aortic, urologic,
tc.). The type of DES included both ﬁrst-generation (sirolimus-
luting stent and paclitaxel-eluting stent) and second-generation
zotarolimus-eluting stent, everolimus-eluting stent, andbiolimus-
luting stent).
xclusion criteria
The exclusion criteria were the patients who underwent body
urface surgery (ophthalmology and dermatology), and patients
ho did not require hospitalization. We excluded the patients who
eceived only balloon angioplasty or aspiration.
vent deﬁnitions
The perioperative complicationswere deﬁned as the occurrence
f MACE and bleeding in hospital. Any perioperative myocar-
ial infarction (MI) and ST was considered as MACE. ST was
eﬁned according to the Academic Research Consortium deﬁni-
ion [7]. Bleeding complications were categorized as major and
inor bleeding as previously reported [8]. In brief, major bleeding
as deﬁned as bleeding requiring transfusion, intracranial bleed-
ng, clinical overt signs of hemorrhage associated with a drop in
emoglobin of 5 g/dl, and fatal bleeding that resulted directly in
eath in 7 days. Minor bleeding was deﬁned as clinically overt
leeding resulting in hemoglobin drop of 3–5g/dl [8].
tatisticsDescriptive results were expressed as frequency and percent-
ge for categorical variables, and they were compared using the
hi square test (or Fisher exact test for small samples). For con-
inuous variables, statistics were expressed as mean± SD and were
Fig. 1. The ﬂowchart of this study. APT, antiplatelet therapy; DAPTdiology 64 (2014) 334–338 335
analyzedusing Student’s t-test. Statistical analyseswereperformed
using StatView (SAS Institute Inc., Cary, NC, USA).
Results
A total of 1794 patients underwent stent deployment in our
institution between January 1st, 2008 and December 31st, 2011.
Among them, 198 patients also underwent NCS; the DAPT group
included 63 patients and the SAPT group included 88 patients
(Fig. 1). Mean age was 69.4±8.3 years in the DAPT group and
70.3±8.7 years in the SAPT group, and 70.4±7.8 years overall
(p=ns) (Table 1). The number of DES implantations was 53 (84.1%)
in the DAPT group and 54 (61.3%) in the SAPT group. Patients tak-
ing anti-coagulants were 15.9% in the DAPT group and 11.4% in
the SAPT group (Table 2). Aortic surgery and abdominal surgery
were performed more frequently in the SAPT group, while periph-
eral vascular surgery and urologic surgery were more frequently
seen in the DAPT group (Table 3). The frequency of bleeding was
signiﬁcantly higher in the DAPT group (9.5%) compared with the
SAPT group (2.3%, p=0.049). Two patients who suffered bleeding
during operation in the SAPT group did not use heparin-bridge in
the perioperative period. Of these two patients, blood transfusion
was required in one patient, and re-operation was required in the
other (Tables 4 and 5). Seven out of eight patientswhohad bleeding
eventswerepatientswhoreceivedDES.Nopatientdied frombleed-
ing (Table 6). No patient experienced ST in either group during the
observational period. NCS after stent deployment was performed
during 328±290 days.
Discussion
The present study showed that the risk of bleeding during the
perioperative period was signiﬁcantly higher in the DAPT group.
There was no difference in risk between with or without heparin-
bridge in the SAPT group.
Current guidelines of the European Society of Cardiology or
ACC/AHA provide information on how to manage cardiovascular
risk during the non-cardiac perioperative period [6,9]. Given the
lack of prospective randomized clinical trials, recommendations
are mostly dependent on experts’ opinions and retrospective
studies.
, dual antiplatelet therapy; SAPT, single antiplatelet therapy.
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Table 1
The baseline characteristics 1.
Overall (n=151) DAPT (n=63) SAPT (n=88) p
Age (years) 70.4±8.8 69.4±8.3 70.3±8.7 ns
Male 124 (82.1%) 43 (68.3%) 81 (92.0%) 0.002
BMI (kg/m2) 23.9±3.4 23.9±3.4 23.9±3.3 ns
Medical history
Ischemic heart disease 151 (100%) 63 (100%) 88 (100%) ns
Congestive heart failure 36 (23.8%) 24 (38.1%) 12 (13.6%) 0.0005
Renal impairment
(Cre >2.0mg/dl)
33 (21.8%) 21 (33.3%) 12 (13.6%) 0.004
Diabetes mellitus 63 (41.7%) 29 (46.0%) 34 (38.6%) ns
Hypertension 125 (82.8%) 57 (90.4%) 68 (77.3%) 0.03
Dysplipidemia 124 (82.1%) 53 (84.1%) 71 (80.7%) ns
History of MI 75 (49.6%) 47 (74.6%) 32 (36.4%) <0.0001
History of stroke 16 (10.6%) 7 (11.1%) 9 (10.2%) ns
Medical therapy
ACE-inhibitor/ARB 104 (68.9%) 52 (82.5%) 52 (59.1%) 0.002
Beta blocker 103 (68.2%) 48 (76.2%) 55 (62.5%) ns
Statin 138 (91.4%) 61 (96.8%) 77 (87.5%) 0.04
Diuretics 45 (29.8%) 28 (44.4%) 17 (19.3%) 0.0009
Calcium antagonist 62 (41.1%) 29 (46.0%) 33 (37.5%) ns
Insulin 29 (19.2%) 19 (30.2%) 10 (11.4%) 0.004
Table 2
The baseline characteristics 2.
Overall (n=151) DAPT (n=63) SAPT (n=88) p
Medical therapy 2
Aspirin 151 (100%) 63 (100%) 88 (100%) ns
Thienopyridine 114 (75.5%) 63 (100%) 51 (58.0%) 0.001
Anti-coagulant 20 (13.2%) 10 (15.9%) 10 (11.4%) ns
Coronary stent 0.002
BMS 44(26.4%) 10 (15.9%) 34 (38.6%)
DES 107 (70.9%) 53 (84.1%) 54 (61.3%)
SES 39 20 19
PES 31 17 14
ZES 3 0 3
EES 27 15 20
BES 1 1 0
Duration from PCI (day) 328±290 356±406 357±347 ns
Table 3
The baseline characteristics 3 (type of surgery).
Overall (n=151) DAPT (n=63) SAPT (n=88) p
Type of surgery <0.0001
Aorta 45 (29.8%) 2 (3.2%) 43 (48.8%)
Abdominal 20 (13.2%) 6 (9.5%) 14 (15.9%)
Vessel peripheral 25 (16.6%) 15 (23.8%) 10 (11.4%)
Urologic 21 (13.9%) 16 (25.4%) 5 (5.8%)
Pacemaker/ICD/CRT-D 15 (9.9%) 11 (17.5%) 4 (4.5%)
Orthopedics 7 (4.6%) 5 (7.9%) 2 (2.3%)
ENT (ear/nose/throat) 4 (2.6%) 4 (6.3%) 0
B
s
S
[
T
TNeurosurgery 2 (1.3%)
Oral and maxillofacial 5 (3.3%)
Other 6 (4.0%)
leeding eventsVan Kuijk et al. [10] showed that the mean bleeding risk from
tudies in which adequate information was available was 4.1% for
APT versus 14.7% for DAPT. In a meta-analysis by Burger et al.
11], including a total of 49,590 patients undergoing NCS, it was
able 4
he clinical outcome. The frequency of bleeding and stent thrombosis.
Overall (n=151) DA
Major bleeding 5 (3.3%) 4 (6
Minor bleeding 3 (2.0%) 2 (3
CVD event 0 0
Total 8 (5.3%) 6 (91 (1.6%) 1 (1.1%)
0 5 (5.7%)
4 (3.2%) 2 (2.3%)
concluded that aspirin continuation led to increased bleeding
events by a factor of 1.5. However, this increase did not lead to
a higher level of the severity of bleeding complications or fatal
bleeding except in intracranial surgery and possibly transurethral
prostatectomy. Tokushige et al. showed that Japanese patients
who underwent NCS in the DAPT group had bleeding events more
PT (n=63) SAPT (n=88) p
.3%) 1 (1.1%) ns
.2%) 1 (1.1%) ns
0 ns
.5%) 2 (2.3%) 0.049
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Table 5
The clinical outcome. The frequency of bleeding and stent thrombosis.
Overall (n=151) DAPT (n=63) SAPT (n=88)
Heparin(+) (n=20) Heparin(−) (n=68)
Major bleeding 5 (3.3%) 4 (6.3%) 0 1 (1.4%)
Minor bleeding 3 (2.0%) 2 (3.2%) 0 1 (1.4%)
CVD event 0 0 0 0
Total 8 (5.3%) 6 (9.5%) 0 2 (2.8%)
Table 6
The characteristics of cases of bleeding events.
Patient Age Gender Type of surgery Stent Antiplatelet
therapy
Anti coagulant Emergency Time from
PCI
Bleeding Complication
A 59 M AAA BMS SAPT Warfarin (off) N 94 days Minor Hb 12.4→8.5
B 72 F ENT (ear/nose/throat) DES DAPT Warfarin (heparin-bridge) N 558 days Major Transfusion 4U
C 70 M Urologic DES DAPT N N 219 days Minor Discontinue clopdgrel
D 79 M Abdominal DES DAPT N Y 512 days Major Transfusion
E 70 M Urologic DES DAPT N N 191 days Minor Discontinue clopdgrel
F 75 M Neurosurgery DES DAPT N Y 246 days Major Intra-cranial
bleeding+ re-operation
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requently than the SAPT group [12]. Moreover, withdrawal of
spirin was associated with a higher incidence of cardiac, cerebral,
nd peripheral vascular events [11]. Similar to previous reports,
ur study showed the frequency of bleeding risk in the DAPT group
as signiﬁcantly higher than that in the SAPT group. APT should be
educed to single in surgeries which have high risk of bleeding.
tent thrombosis
In a prospective multicenter observational study of 1134 NCS
rocedures (82%performedwithin1year after PCI),MACEoccurred
n10.9%ofpatients [13].Amultivariateanalysis identiﬁedcomplete
PT interruption 5 days prior to NCS as well as creatinine clear-
nce 30ml/min, pre-operative hemoglobin 10g/dl, and urgent
nd high-risk surgery as signiﬁcant predictors for MACE. Activa-
ion of hemostasis is associated with persistent high on-treatment
latelet reactivity, a well-known risk factor for ST [14]. Although
here was no event of ST in our study, the risk of ST is of concern in
atients receiving no APT in the perioperative period.
eparin-bridge
It remains unclear whether heparin-bridge is useful. A 103-
atient study (unknown stent type: 77%) undergoing NCS 1 year
fter PCI evaluated addition of either unfractionated or low-
olecular weight heparin (LMWH) perioperatively in addition to
ontinuation of some type of APT (aspirin 85%, clopidogrel 44%)
15]. Although the incidence of signiﬁcant bleeding was low, the
isk of overall adverse events was high (approximately 44%). A
revious study showed that heparin-bridge alternative for antico-
gulation before pacemaker or deﬁbrillator surgery did not reduce
hromboembolic events and increased bleeding events [16]. In the
resent study, the heparin-bridge alternative for APT did not sig-
iﬁcantly change the bleeding or cardiovascular risk. Given the
aucity of data, the value of heparin or LMWH is uncertain.
imitationsOur study has the inherent limitations of a retrospective design.
here is a possibility of referral bias, and the care of thepatientswas
ot controlled by a study protocol. The type of stent used at the PCIN 388 days Major Intra-cranial
bleeding+ re-operation
N 798 days Major Transfusion 4U
procedure and duration of discontinuation of APT was determined
by the treating physician. Although SAPT appeared relatively safe
in this study, there are no data to support safety of SAPT in neu-
rosurgery, which allows little safety margin for bleeding. Further
study is warranted to evaluate appropriate APT in patients who
received intracoronary stents.
Conclusions
The frequency of bleeding events was higher in the DAPT group.
Both bleeding and cardiovascular events with aspirin alone were
low in our study. It may be safe to undergo NCS with SAPT after PCI.
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